Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03996369 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT03996369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03996369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2020
Completion date
December 7, 2021
Enrollment
354 (actual)
Sites
407

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis